A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis - Wikidata - wikimedia - TriplyDB

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

http://www.wikidata.org/entity/Q35076974

about

Role of isavuconazole in the treatment of invasive fungal infections Isavuconazole: A New Broad-Spectrum Triazole Antifungal Agent Isavuconazole: A New Option for the Management of Invasive Fungal Infections.Activity of Isavuconazole and Other Azoles against Candida Clinical Isolates and Yeast Model Systems with Known Azole Resistance Mechanisms.Isavuconazole Population Pharmacokinetic Analysis Using Nonparametric Estimation in Patients with Invasive Fungal Disease (Results from the VITAL Study)Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults Isavuconazonium: first global approval.The 'cephalosporin era' of triazole therapy: isavuconazole, a welcomed newcomer for the treatment of invasive fungal infections.Isavuconazole: Pharmacology, Pharmacodynamics, and Current Clinical Experience with a New Triazole Antifungal Agent.Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations.Antifungal agents and liver toxicity: a complex interaction.Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections.Isavuconazole: is there a need for a new antifungal?A Review of the Clinical Pharmacokinetics and Pharmacodynamics of Isavuconazole.Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations.Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy.

P2860

Q26740837-D32D1445-FB9B-440D-8F76-0BCC09E809D5 Q28082019-B3E9889D-56D0-44CB-B377-AFCAED854549 Q34474946-1C621421-8D00-4F46-999B-E512A0FB8039 Q36439061-ADB36AA7-85C9-43E0-886A-181798C4A828 Q37119937-2EA693CF-41BE-4368-9A51-E74980C042B0 Q37631935-E8187C4D-083F-4321-AE70-88ADCCA73C65 Q38436002-4145917E-4961-4693-98DF-CA8521F8D893 Q38534865-66D15B91-CFF2-4F15-8572-9E769E9E4B69 Q38644817-117964A6-598D-47F3-A5ED-C5DC4F465F2B Q38738090-426B11C4-178F-432F-A4A5-3B20B0D84228 Q38858839-04E2E02C-F439-41D2-9CC3-6FD250B6259C Q38939506-10F7E52E-4EBB-4F76-AA72-5F8968EB021B Q40273512-C46A6D6A-60EF-4461-BB8E-15284532F384 Q47660181-A964DEAA-9DFE-43C1-B669-80DCB3E2CBEC Q47697145-AA3C77B0-1942-4836-AF8D-8EB299AB51CC Q54214603-FDA568C2-41C8-4989-90C3-6750F8DCC97B

P2860

A phase 2, randomized, double-blind, multicenter trial to evaluate the safety and efficacy of three dosing regimens of isavuconazole compared with fluconazole in patients with uncomplicated esophageal candidiasis

http://www.wikidata.org/entity/Q35076974

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

name

A phase 2, randomized, double- ...... licated esophageal candidiasis

@ast

A phase 2, randomized, double- ...... licated esophageal candidiasis

@en

type

label

A phase 2, randomized, double- ...... licated esophageal candidiasis

@ast

A phase 2, randomized, double- ...... licated esophageal candidiasis

@en

prefLabel

A phase 2, randomized, double- ...... licated esophageal candidiasis

@ast

A phase 2, randomized, double- ...... licated esophageal candidiasis

@en

P1433

Q35076974-19D0C7B1-CF5D-4F93-8D57-942414E2DDEB

P1476

Q35076974-7E302194-7EFF-4068-888C-D59CCD442F0F

P2093

Q35076974-14AC6E4D-0131-4BEA-9CFA-E88F8796183D

Q35076974-165A0F7B-72C3-4DAE-9D9A-F5AFB23029FA

Q35076974-586A7E1F-102F-4479-A98B-375B1BB57D3B

Q35076974-AFC92D4B-FFBD-4178-B4CB-3C4976D71CE8

P2860

Q35076974-00DE2BC4-8B53-443F-B9B4-8451F5C67C8D

Q35076974-06ADEA70-6C1D-4DBD-8E8B-26BF218DC8BA

Q35076974-09DC92A5-501F-48D3-8CE5-605401240D47

Q35076974-11A3E301-09B5-4837-8376-BD3333388419

Q35076974-1C65837E-0B8D-4522-AF96-CEB6180FD3D6

Q35076974-3F2D4D9B-3AD3-4440-9D49-03434FE7E308

Q35076974-4635723E-38ED-40C3-8F9C-299788248465

Q35076974-464264FD-BC38-4055-A408-226B5DB502C6

Q35076974-539462C2-7BD0-428A-AD26-C60E461278D7

Q35076974-5F076F62-6C9C-437F-8239-1CFFA7D8BFD5

P304

Q35076974-D12DDF18-CC1E-4F2A-B7CC-C69A6B2B2D54

P31

Q35076974-DAED19D1-66C4-47AE-94B3-3A9D0898631B

P356

Q35076974-E170739F-C6B7-453B-91CE-A650D3AF33C6

P407

Q35076974-9B34D8D2-65C1-44BE-BD76-5691AC410B77

P433

Q35076974-5BBC9635-4D8C-4791-B5C6-37E80970C74B

P478

Q35076974-6212486C-7C45-415E-BF51-F691B4DB5FE9

P577

Q35076974-77F24629-975C-45B3-8465-9752A7FD8849

P5875

Q35076974-6A2956D7-9843-46C0-BDC7-654D177A5471

P698

Q35076974-55D07199-C777-4C20-BC7C-B953AD3D4BCF

P921

Q35076974-1BC082BE-3F5F-4690-9D09-F2E664D509E8

Q35076974-5DDC7FCC-B0CF-4813-91F8-3B607B7D95D9

Q35076974-75F60C28-DF06-4231-9ADE-DC944D60DF1B

Q35076974-C1DBD488-B76C-4B9C-B4FD-F8D204BA56D0

P932

Q35076974-BB99E19E-07C0-4916-9CFB-A58725B692A1

P356

P1433

Antimicrobial Agents and Chemotherapy

P1476

A phase 2, randomized, double- ...... licated esophageal candidiasis

@en

P2093

A-H Schmitt-Hoffmann

http://www.w3.org/2001/XMLSchema#string

J Viljoen

http://www.w3.org/2001/XMLSchema#string

M Ghannoum

http://www.w3.org/2001/XMLSchema#string

N Azie

http://www.w3.org/2001/XMLSchema#string

P2860

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

Regional data analysis of Candida non-albicans strains collected in United States medical sites over a 6-year period, 2006-2011.

Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America.

Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study

High Accuracy of Common HIV-Related Oral Disease Diagnoses by Non-Oral Health Specialists in the AIDS Clinical Trial Group.

In vitro activities of isavuconazole and comparator antifungal agents tested against a global collection of opportunistic yeasts and molds.

Isavuconazole pharmacodynamic target determination for Candida species in an in vivo murine disseminated candidiasis model.

Efficacy of isavuconazole, voriconazole and fluconazole in temporarily neutropenic murine models of disseminated Candida tropicalis and Candida krusei.

Isavuconazole (BAL4815) pharmacodynamic target determination in an in vivo murine model of invasive pulmonary aspergillosis against wild-type and cyp51 mutant isolates of Aspergillus fumigatus.

Isavuconazole therapy protects immunosuppressed mice from mucormycosis.

P304

1671-1679

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.04586-14

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

270656017

http://www.w3.org/2001/XMLSchema#string

P698

25561337

http://www.w3.org/2001/XMLSchema#string

P921

isavuconazonium sulfate

phase II clinical trial

multicenter trial

P932

4325824

http://www.w3.org/2001/XMLSchema#string